Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

NCT05312879 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT05312879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05312879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 30, 2022
Completion date
May 7, 2030
Enrollment
466 (estimated)
Sites
318

Conditions

As the registry lists them; a condition with its own page is linked.

proteinuric kidney disease